Samsung Biologics announced on Thursday that it has earned the prestigious Platinum rating from EcoVadis, a global sustainability assessment organization. This top-tier recognition is awarded to only the top 1% of companies in EcoVadis’ ESG evaluation.
EcoVadis, established in France in 2007, annually assesses over 150,000 companies across 185 countries. The evaluation covers four key areas: environmental impact, labor practices and human rights, ethics, and sustainable procurement. Based on their performance, companies receive ratings ranging from Bronze to Platinum.
EcoVadis’ ESG assessments are widely recognized as a benchmark for supply chain sustainability. Industry giants like GlaxoSmithKline (GSK) and AstraZeneca (AZ) reportedly rely heavily on these evaluations to gauge the sustainability of their supply networks.
After securing a Gold rating in 2024, Samsung Biologics has now achieved the coveted Platinum status in the 2025 assessment. This highest-level rating demands excellence across the board, from policy development and implementation to performance management and transparency in reporting. It’s a distinction reserved for the top 1% of all evaluated companies.
Samsung Biologics earned high marks for its comprehensive and effective ESG initiatives across all four assessment areas. In environmental management, the company was lauded for minimizing its ecological footprint through advanced water management practices, including rigorous wastewater quality assessments and the replacement of hazardous materials.
The company’s efforts in labor and human rights were recognized for creating a safe and equitable workplace and for implementing robust employee development programs. In ethics, Samsung Biologics enhanced its governance by establishing global standard ethical management indicators and conducting annual assessments.
To support sustainable procurement, the company demonstrated its commitment by providing carbon-neutrality training to its purchasing department, thereby strengthening ESG practices across its supply chain.
John Lim, CEO of Samsung Biologics, said that securing the Platinum rating reaffirmed the company’s position as an ESG leader in the global pharmaceutical and biotech sector. He added that the company remained committed to meeting the expectations of its clients and stakeholders through responsible ESG management, fulfilling its role as a dependable CDMO partner.
